美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Brookfield Real Assets Income Fund Inc.

13.21

-0.0100-0.08%

盤後：13.210.00000.00%17:49 EST

成交量：19.72萬

成交額：260.59萬

市值：7.30億

市盈率：9.40

高：13.25

開：13.22

低：13.17

收：13.22

52周最高：13.59

52周最低：11.87

股本：5,525.47萬

流通股本：5,524.59萬

量比：0.73

換手率：0.36%

股息：1.42

股息率：10.72%

每股收益(TTM):1.41

淨資產收益率：--

總資產收益率：--

市淨率：0.91

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

新聞稿：Vor Bio任命RA Capital的Andrew Levin博士及Forbion的Wouter Joustra為董事會成員

中國TCE投資地圖2025：風暴將至

Anaptysbio, Inc.盤中異動急速上漲5.28%報38.97美元

免疫調節原研藥賽能缺貨致價格翻倍！已有藥店限購，相關企業回應：漲價是市場行為

红星资本局

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/RA"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":13.21,"timestamp":1770670800000,"preClose":13.22,"halted":0,"volume":197206,"hourTrading":{"tag":"盘后","latestPrice":13.21,"preClose":13.21,"latestTime":"17:49 EST","volume":119,"amount":1576.18,"timestamp":1770677377823,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0007564296520423439,"floatShares":55245934,"shares":55254696,"eps":1.406,"marketStatus":"未開盤","change":-0.01,"latestTime":"02-09 16:00:00 EST","open":13.22,"high":13.25,"low":13.17,"amount":2605910.65093,"amplitude":0.006051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.406,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":13.22,"dividendRate":0.107184,"preHourTrading":{"tag":"盘前","latestPrice":13.1626,"preClose":13.22,"latestTime":"09:22 EST","volume":183,"amount":2408.386689,"timestamp":1770646947013,"change":-0.0574,"changeRate":-0.004342,"amplitude":0.000197},"postHourTrading":{"tag":"盘后","latestPrice":13.21,"preClose":13.21,"latestTime":"17:49 EST","volume":119,"amount":1576.18,"timestamp":1770677377823,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.734349},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.734349,"shares":55254696,"dividePrice":1.4159,"high":13.25,"amplitude":0.006051,"preClose":13.22,"low":13.17,"week52Low":11.87,"pbRate":"0.91","week52High":13.59,"institutionHeld":0,"latestPrice":13.21,"eps":1.406,"divideRate":0.107184,"volume":197206,"delay":0,"ttmEps":1.406,"open":13.22,"prevYearClose":12.96,"prevWeekClose":13.22,"prevMonthClose":13.02,"prevQuarterClose":12.96,"fiveDayClose":13.07,"twentyDayClose":12.88,"sixtyDayClose":13.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-03-12","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-12","defaultRemindTime":1773322200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-12","currency":"USD","dateTimestamp":1773288000000,"payDate":"2026-03-26"},{"date":"2026-02-05","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-05","defaultRemindTime":1770301800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-19","payableDate":"2026-02-05","currency":"USD","dateTimestamp":1770267600000,"payDate":"2026-02-19"},{"date":"2026-01-08","symbol":"RA","amount":0.118,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-08","defaultRemindTime":1767882600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-22","payableDate":"2026-01-08","currency":"USD","dateTimestamp":1767848400000,"payDate":"2026-01-22"},{"date":"2025-12-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-11","defaultRemindTime":1765463400000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-11","currency":"USD","dateTimestamp":1765429200000,"payDate":"2025-12-26"},{"date":"2025-11-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-13","defaultRemindTime":1763044200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-13","currency":"USD","dateTimestamp":1763010000000,"payDate":"2025-11-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1171369174","title":"新聞稿：Vor Bio任命RA Capital的Andrew Levin博士及Forbion的Wouter Joustra為董事會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=1171369174","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171369174?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 05:02","pubTimestamp":1766523754,"startTime":"0","endTime":"0","summary":"波士顿，马萨诸塞州，2025年12月23日-- Vor Biopharma Inc.，一家致力于改变自身免疫疾病治疗的临床阶段生物技术公司，今天宣布任命RA Capital Management的合伙人Andrew Levin博士和Forbion的普通合伙人Wouter Joustra加入其董事会。此次任命是在公司最近宣布的1.5亿美元PIPE融资后进行的，两个投资者均参与了此次融资。Levin博士填补了此前由RA Capital的总法律顾问Sarah Reed担任的职位，后者已辞去董事会职务。本新闻稿中的前瞻性声明包括Vor Bio关于telitacicept发展计划的陈述，以及其他非历史性事实的陈述。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2585459696","title":"中國TCE投資地圖2025：風暴將至","url":"https://stock-news.laohu8.com/highlight/detail?id=2585459696","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585459696?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 15:28","pubTimestamp":1763969338,"startTime":"0","endTime":"0","summary":"如曲妥珠单抗治疗晚期HER2阳性乳腺癌，利妥昔单抗治疗B细胞淋巴瘤。此外，TCE有望走向自免适应症。其中，全球首创的CD19/BCMA/CD3三抗LBL-051通过NewCo模式与Aditum Bio合作，交易总额达6.14亿美元，创下国内临床前TCE管线授权纪录。无独有偶，康诺亚在2025年1月又联合诺诚健华将CD20/CD3双抗CM355非肿瘤适应症权益授予RTW投资的Prolium，分得875万美元首付款，5.025亿美元里程碑潜在收益以及Prolium的部分股权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1763967554011359814","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["RA","MSS","BK4113"],"gpt_icon":0},{"id":"2585515990","title":"Anaptysbio, Inc.盤中異動 急速上漲5.28%報38.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585515990","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585515990?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 22:50","pubTimestamp":1763650225,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日22时50分，Anaptysbio, Inc.股票出现异动，股价急速上涨5.28%。截至发稿，该股报38.97美元/股，成交量2.351万股，换手率0.08%，振幅3.89%。Anaptysbio, Inc.股票所在的生物技术行业中，整体涨幅为1.51%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Annexon, Inc.、Design Therapeutics, Inc.涨幅较大，Psyence Biomedical Ltd.、Clearmind Medicine Inc.、Kazia Therapeutics Limited较为活跃，换手率分别为954.91%、37.38%、14.49%，振幅较大的相关个股有Immutep Ltd、Biorestorative Therapies, Inc.、康乃德生物，振幅分别为102.05%、21.68%、20.32%。Anaptysbio, Inc.公司简介：AnaptysBio Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120225026a706fe38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120225026a706fe38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4132","ANAB","BK4139","RA","AD"],"gpt_icon":0},{"id":"2578634704","title":"免疫調節原研藥賽能缺貨致價格翻倍！已有藥店限購，相關企業回應：漲價是市場行為","url":"https://stock-news.laohu8.com/highlight/detail?id=2578634704","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578634704?lang=zh_tw&edition=fundamental","pubTime":"2025-10-26 17:37","pubTimestamp":1761471463,"startTime":"0","endTime":"0","summary":"“赛能赶上黄金了，一天一个价。”“赛能是不是要停产了，哪里的医院还能开？”近日，红星资本局注意到，硫酸羟氯喹片原研药赛能缺货、涨价的消息在社交平台上传播。资料显示，硫酸羟氯喹是一种广泛应用于治疗自身免疫性疾病的药物，原研药赛能由知名法国药企赛诺菲（Sanofi）生产，2000年在国内获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510263544477885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4077","SLE","RA"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RA\",params:#limit:6,delay:false,,,undefined,":[]}}